STOCK TITAN

AMYRIS, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Amyris, Inc. (Nasdaq: AMRS) announced Q1 2023 financial results. Core revenue of $56.1 million exceeded guidance by 12%. Cash operating expense down 4% compared to Q1 2022 and down 24% versus Q4 2022. Completed strategic partnership with Givaudan for $200 million upfront cash.
Positive
  • Core revenue exceeded guidance by 12% in Q1 2023, reaching $56.1 million. Cash operating expense decreased by 4% compared to Q1 2022 and by 24% compared to Q4 2022. The company completed a strategic partnership with Givaudan, receiving $200 million upfront cash.
Negative
  • None.
  • Core revenue of $56.1 million exceeded Q1 guidance of $49.9 million
  • Cash operating expense down 4% compared to Q1 2022 and down 24% versus Q4 2022
  • Completed strategic partnership with Givaudan on April 3 for $200 million upfront cash

EMERYVILLE, Calif., May 9, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the first quarter ended March 31, 2023.   

Q1 2023 Core revenue of $56.1 million decreased 3% compared to Q1 2022 and exceeded guidance by 12%. Consumer revenue of $34.2 million decreased 1% compared to Q1 2022, as the company focused on liquidity and cost efficiencies to seek to maximize returns on marketing expense. Technology Access revenue of $21.9 million was down 5% compared to Q1 2022. R&D collaboration revenue increased 3% compared to Q1 2022 with the addition of new contract research programs. Gross profit of $11.6 million (21% of revenue) increased $1.0 million (2 percentage points) versus Q1 2022 and improved $17.8 million (29 percentage points) sequentially versus Q4 2022 due to lower freight expenses as well as a favorable mix of higher margin revenue. Cash operating expense of $112.8 million improved 4% compared to Q1 2022 and improved 24% sequentially compared to Q4 2022. Principal drivers for the improvement were reduced consumer brand selling expense and lower freight costs.

The company continues to execute its strategic agenda with a keen focus on cost efficiency, capital structure, and liquidity. The company is in the process of a strategic review of all aspects of its cost structure in support of the company's Fit-to-Win initiatives, with the objective to accelerate cost and efficiency improvements. Use of cash for operating and investing activities decreased sequentially for each of the past five quarters beginning with $199.7 million in Q1 2022 through $94.8 million in Q1 2023 as the result of a focused effort on cost containment and the need to navigate liquidity constraints.

The company expanded its Technology Access partnerships by closing the strategic transaction with Givaudan for the worldwide licensing of certain cosmetic ingredients, the highest per molecule transaction completed in the company's history. The transaction yielded up to $350 million, with $200 million of upfront cash received and used for general corporate purposes as well as to fund the $49 million purchase of Aprinnova joint venture interests, which enabled the Givaudan transaction. During the first quarter and as part of consumer portfolio prioritization, the company exited the EcoFabulousTM brand and reorganized the Beauty Labs business.

"During Q1, we were very focused on our liquidity and cost control efforts," commented John Melo, President and Chief Executive Officer. "We expanded the Fit-to-Win scope to all aspects of our operations and entered into a strategic review of our cost structure and liquidity plans to continue to support growth across the portfolio and achieve profitability. We have much more to do on our Fit-to-Win agenda. To fully leverage our assets and drive enterprise value, we are focused on efficiency, lowering costs, and simplifying our portfolio."

Income Statement


(millions and %)


Q122A

Q222A

Q322A

Q422A

2022A


Q123A


YoY%
Change

QoQ %
Change













Consumer


34.6

43.0

46.6

52.8

176.9


34.2


-1 %

-35 %

Technology Access


23.2

22.2

24.6

23.0

92.9


21.9


-5 %

-5 %

Core revenue1


57.7

65.2

71.1

75.8

269.8


56.1


-3 %

-26 %













Non-GAAP Gross Profit


10.6

11.1

6.7

(6.2)

22.2


11.6


9 %

288 %













Non-GAAP Cash Operating Expense


(117.1)

(136.7)

(137.8)

(148.3)

(539.9)


(112.8)


4 %

24 %













Adjusted EBITDA


(106.5)

(125.6)

(131.0)

(154.5)

(517.7)


(101.2)


5 %

34 %

1 Core revenue comprises Consumer and Technology Access revenue. Technology Access includes ingredient product revenue, R&D collaboration, and technology licenses. Core revenue excludes strategic transactions. Totals may not foot due to rounding.

Q1 2023 Financial Highlights

  • Core revenue of $56.1 million decreased 3% compared to Q1 2022. Core revenue included Consumer revenue of $34.2 million, which decreased 1% relative to Q1 2022, and Technology Access revenue of $21.9 million, which decreased 5% compared to Q1 2022.
  • Q1 Consumer revenue decline was driven by lower Biossance® revenue due to lower marketing and media spend, offset in part by the launch of our 4U by TiaTM brand at Walmart as well as increased MenoLabs® direct-to-consumer revenue. In Q1 2023, direct-to-consumer sales represented 48% of total consumer revenue, compared to 53% in Q4 2022. Biossance®, Pipette®, JVN, and Rose Inc.® products were available in more than 15,750 physical locations compared to approximately 3,000 in Q1 2022.
  • Q1 Technology Access revenue included Ingredients product revenue of $8.9 million, which decreased 18% compared to Q1 2022, reflecting continuing supply and working capital constraints as the business transitioned from higher cost toll manufacturing to lower cost internal sourcing from the new fermentation plant in Brazil. R&D collaboration revenue of $3.6 million improved relative to the prior year with growth driven by several new contract research programs. Technology license revenue from earn-outs totaled $9.5 million.
  • Non-GAAP gross profit of $11.6 million in Q1 2023 was 21% of revenue. Non-GAAP gross profit improved from $10.6 million or 18% of revenue in Q1 2022, reflecting lower freight expenses as well as a favorable mix of higher margin revenue.
  • Non-GAAP cash operating expense of $112.8 million was 4% lower than Q1 2022 and 24% lower than Q4 2022, primarily due to lower marketing and media spend as a result of cost focus and working capital constraints.
  • Adjusted EBITDA of ($101.2) million represented a $5.3 million improvement over Q1 2022 and a $53.3 million sequential improvement over Q4 2022 due to lower operating expenses, including lower marketing and media spend.
  • Q1 2023 net loss was $193.3 million ($0.53 loss per diluted share or $0.34 loss per diluted share when excluding the below referenced items) compared to a net loss of $107.3 million ($0.37 loss per diluted share) in Q1 2022. This included a favorable non-cash change in fair value of acquisition-related contingent consideration of $28.5 million ($0.08 per diluted share) and non-cash asset impairments totaling $95.4 million ($0.26 per diluted share) related to exiting the EcoFabulous brand and reorganizing the Beauty Labs business. In addition, non-cash mark-to-market adjustments related to changes in the fair value of debt and derivatives were $3.6 million unfavorable in Q1 2023 ($0.01 per diluted share) and $22.6 million favorable in Q1 2022 ($0.07 per diluted share).
  • Total cash at the end of Q1 2023 was $17.5 million compared to $70.6 million at the end of Q4 2022.

Financial Status and Outlook

Our current outlook for the full year 2023, including revenue guidance provided by the company on March 15, 2023, remains unchanged.

In connection with the company's ongoing strategic review, as previously communicated on April 24, 2023, the company is focused on cost efficiency, capital structure, and liquidity required to fund the business.

The company updated its going concern disclosure in its quarterly report on Form 10-Q and has signed forbearance agreements with the company's lenders, Foris Ventures, LLC, Perrara Ventures, LLC, and DSM Finance B.V. relating to the maturity of an aggregate $92.5 million of debt principal. The lenders have agreed to forbear from exercising any rights and remedies with respect to certain payment defaults until June 23, 2023.

 

FINANCIAL RESULTS AND NON-GAAP INFORMATION

To supplement our financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures that we believe are helpful in understanding our financial results. These non-GAAP financial measures are among the factors management uses in planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to Amyris' historical performance as well as comparisons to the operating results of other companies. Management believes these non-GAAP financial measures, when considered together with financial information prepared in accordance with GAAP, can enhance investors' and analysts' abilities to meaningfully compare our results from period to period, identify operating trends in our business, and track and model our financial performance. In addition, our management believes that these non-GAAP financial measures allow for greater transparency into the indicators used by management to understand and evaluate our business and make operating decisions.

Non-GAAP financial information is not prepared under a comprehensive set of accounting rules, and therefore, should only be read in conjunction with financial information reported under GAAP in order to understand Amyris' operating performance. A reconciliation of the non-GAAP financial measures presented in this release to the most directly comparable GAAP financial measure, is provided in the tables attached to this press release.

Our Non-GAAP financial measures include the following:

Non-GAAP Gross Profit is calculated as GAAP revenue less cost of products sold excluding certain inventory write-offs, manufacturing capacity fee adjustments, stock-based compensation expense, depreciation, and amortization.

Non-GAAP Cash Operating Expense is calculated as GAAP Operating Expense excluding stock-based compensation, depreciation, amortization, M&A transaction expense, change in fair value of acquisition-related contingent consideration, restructuring, and impairment.

EBITDA is calculated as GAAP net income (loss) excluding interest expense, income taxes, depreciation and amortization.

Adjusted EBITDA is calculated as EBITDA excluding income/loss attributable to noncontrolling interest, gain/loss from change in fair value of derivative instruments, gain/loss from change in fair value of debt, other income/expense, gain/loss from investment in affiliate, inventory write-offs, M&A transaction expense, stock-based compensation expense, manufacturing capacity fee adjustment, change in fair value of acquisition-related contingent consideration, restructuring, and impairment.

About Amyris

Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-MarketTM technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit http://www.amyris.com

Amyris, the Amyris logo, EcoFabulous and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries in the U.S. and/or other countries.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as Amyris' successful execution of its strategic agenda including Fit-to-Win initiatives; its 2023 outlook and goals, including cost reduction initiatives, growth, profitability and other financial and business goals; and Amyris' expectations regarding the ongoing strategic review of its cost structure and 2023 plan and the timing of completion thereof. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris' liquidity and ability to operate as a going concern, risks related to its financing activities including successfully obtaining waivers and amendments of outstanding loan agreements, risks related to potential delays or failures in completing planned strategic transactions and dispositions, risks related to potential delays or failures in development, regulatory approval, launch, production and commercialization of products, risks related to global economic trends, inflation and policy measures undertaken to address inflation, the COVID-19 pandemic and any other geopolitical events, including the Ukraine conflict, resulting in global economic, financial and supply chain disruptions that may negatively impact Amyris' business operations and financial results or cause market volatility, risks related to Amyris' reliance on third parties particularly in the supply chain, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

 

Financial Tables Follow

 

Amyris, Inc. 



CONSOLIDATED BALANCE SHEETS



(In thousands)

March 31,
2023
(Unaudited)

December
31, 2022




Assets



Current assets:



Cash and cash equivalents

$      11,245

$     64,437

Restricted cash

71

71

Accounts receivable, net

36,842

45,775

Accounts receivable - related party, net

10,836

6,608

Contract assets

3,872

806

Contract assets - related party

33,679

36,638

Inventories

109,021

111,880

Prepaid expenses and other current assets

38,095

40,146

Total current assets

243,661

306,361

Property, plant and equipment, net

189,645

182,224

Restricted cash, noncurrent

6,135

6,090

Recoverable taxes from Brazilian government entities

30,189

29,472

Right-of-use assets under financing leases, net

147

152

Right-of-use assets under operating leases, net

100,721

97,216

Goodwill

50,456

142,575

Intangible assets, net

45,063

46,938

Other assets

13,662

13,904

Total assets

$    679,679

$   824,932

Liabilities, Mezzanine Equity and Stockholders' Deficit



Current liabilities:



Accounts payable

$    200,067

$   190,486

Accrued and other current liabilities

81,068

73,565

Financing lease liabilities

14

13

Operating lease liabilities

2,484

2,255

Contract liabilities

33

26

Debt, current portion

1,968

1,916

Related party debt, current portion

185,160

118,886

Total current liabilities

470,794

387,147

Long-term debt, net of current portion

675,855

674,891

Related party debt, net of current portion

77,962

97,350

Financing lease liabilities, net of current portion

44

48

Operating lease liabilities, net of current portion

90,986

86,195

Derivative liabilities

4,140

5,403

Acquisition-related contingent consideration

2,241

34,555

Other noncurrent liabilities

5,725

7,053

Total liabilities

1,327,747

1,292,642

Commitments and contingencies



Mezzanine equity:



Contingently redeemable common stock

-

5,000

Contingently redeemable noncontrolling interest

26,058

28,892

Stockholders' deficit:



Common stock

37

36

Additional paid-in capital

2,465,802

2,455,567

Accumulated other comprehensive loss

(56,682)

(64,114)

Accumulated deficit

(3,073,520)

(2,880,178)

Total Amyris, Inc. stockholders' deficit

(664,363)

(488,689)

Noncontrolling interest

(9,763)

(12,913)

Total stockholders' deficit

(674,126)

(501,602)

Total liabilities, mezzanine equity and stockholders' deficit

$    679,679

$   824,932

 

Amyris, Inc. 



CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)




Three Months Ended
March 31,

(In thousands, except shares and per share amounts)

2023

2022




Revenue:



Renewable products

$       40,224

$       43,465

Licenses and royalties

9,482

9,313

Collaborations, grants and other

6,377

4,931

Total revenue

56,083

57,709

Cost and operating expenses:



Cost of products sold

51,081

48,995

Research and development

26,765

26,358

Sales, general and administrative

95,870

106,916

Change in fair value of acquisition-related contingent consideration

(28,503)

-

Restructuring

1,013

-

Impairment

95,386

-

Total cost and operating expenses

241,612

182,269

Loss from operations

(185,529)

(124,560)

Other income (expense):



Interest expense

(12,983)

(5,263)

Gain from change in fair value of derivative instruments

1,263

1,815

Gain (loss) from change in fair value of debt

(4,854)

20,796

Other expense, net

(533)

(3,052)

Total other income (expense), net

(17,107)

14,296

Loss before income taxes and loss from investment in affiliate

(202,636)

(110,264)

Benefit from income taxes

860

820

Loss from investment in affiliate

-

(789)

Net loss

(201,776)

(110,233)

Loss attributable to noncontrolling interest

8,434

2,928

Net loss attributable to Amyris, Inc. common stockholders

$    (193,342)

$    (107,305)




Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic

365,603,738

312,896,452

Loss per share attributable to common stockholders, basic

$         (0.53)

$         (0.34)




Weighted-average shares of common stock outstanding used in computing loss per share of common stock, diluted

365,603,738

323,711,682

Loss per share attributable to common stockholders, diluted

$         (0.53)

$         (0.37)

 

Amyris, Inc. 



EBITDA AND ADJUSTED EBITDA
(Unaudited)




Three Months Ended
March 31,

(In thousands)

2023

2022




Net loss attributable to Amyris, Inc. common stockholders

$    (193,342)

$    (107,305)

Interest expense

12,983

5,263

Income taxes

(860)

(820)

Depreciation and amortization

5,851

3,292

EBITDA

(175,368)

(99,570)




Inventory write-off

4,211

(94)

Change in fair value of acquisition-related contingent consideration

(28,503)

-

Restructuring

1,013

-

Impairment

95,386

-

Manufacturing capacity fee adjustment

-

1,412

M&A transaction expense

566

1,835

Stock-based compensation expense

5,785

11,588

Gain from change in fair value of derivative instruments

(1,263)

(1,815)

Loss (gain) from change in fair value of debt

4,854

(20,796)

Other expense, net

533

3,052

Loss from investment in affiliate

-

789

Loss attributable to noncontrolling interest

(8,434)

(2,928)

Adjusted EBITDA

$    (101,220)

$    (106,527)

 

Amyris, Inc. 



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(Unaudited)




Three Months Ended March 31,

(In thousands)

2023

2022




NON-GAAP GROSS PROFIT



Revenue



Renewable products

$  40,224

$  43,465

Licenses and royalties

9,482

9,313

Collaborations, grants and other

6,377

4,931

Total revenue

$  56,083

$  57,709




Cost of products sold

$  51,081

$  48,995

Manufacturing capacity fee adjustment

-

(1,412)

Inventory write-off

(4,211)

94

Stock-based compensation expense

(66)

(78)

Depreciation and amortization

(2,324)

(490)

Non-GAAP cost of products sold

$  44,480

$  47,109




Non-GAAP gross profit

$  11,603

$  10,600

Non-GAAP gross profit %

21 %

18 %







NON-GAAP CASH OPERATING EXPENSE



Research and development expense

$  26,765

$  26,358

Sales, general and administrative expense

95,870

106,916

Change in fair value of acquisition-related contingent consideration

(28,503)

-

Restructuring

1,013

-

Impairment

95,386

-

GAAP operating expense

190,531

133,274




Stock-based compensation expense

(5,719)

(11,510)

Depreciation and amortization

(3,527)

(2,802)

M&A transaction expense

(566)

(1,835)

Change in fair value of acquisition-related contingent consideration

28,503

-

Restructuring

(1,013)

-

Impairment

(95,386)

-

Non-GAAP cash operating expense

$112,823

$117,127

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amyris-inc-reports-first-quarter-2023-financial-results-301820072.html

SOURCE Amyris, Inc.

FAQ

What was the Q1 2023 core revenue for Amyris, Inc.?

The Q1 2023 core revenue for Amyris, Inc. was $56.1 million, which exceeded guidance by 12%.

How did the cash operating expense change in Q1 2023 compared to Q1 2022?

The cash operating expense decreased by 4% in Q1 2023 compared to Q1 2022.

What was the upfront cash received from the strategic partnership with Givaudan?

Amyris, Inc. received $200 million upfront cash from the strategic partnership with Givaudan.

Amyris Inc

NASDAQ:AMRS

AMRS Rankings

AMRS Latest News

AMRS Stock Data

Petroleum Refineries
Manufacturing
Link
US
Emeryville